Left ventricular assist device-induced molecular changes in the failing myocardium

Current Opinion in Cardiology

Volumn 23, Issue 3, 2008, Pages 206-218

  Soppa, Gopal K R ^a   Barton, Paul J R ^a   Terracciano, Cesare M N ^a   Yacoub, Magdi H ^a  

^a HAREFIELD HOSPITAL   (United Kingdom)

Author keywords

Heart failure; Left ventricular assist device; Molecular mechanisms; Unloading

Indexed keywords

ADRENERGIC RECEPTOR; CALCIUM; CYTOSKELETON PROTEIN; TRANSCRIPTION FACTOR;

APOPTOSIS; CELL SURVIVAL; EXTRACELLULAR MATRIX; HEART FAILURE; HEART MUSCLE CELL; HEART VENTRICLE REMODELING; IMMUNE SYSTEM; PRIORITY JOURNAL; REVIEW;

ANIMALS; HEART FAILURE; HEART-ASSIST DEVICES; HUMANS; MYOCYTES, CARDIAC; SIGNAL TRANSDUCTION; VENTRICULAR REMODELING;

EID: 41749085095     PISSN: 02684705     EISSN: None     Source Type: Journal    
DOI: 10.1097/HCO.0b013e3282fc7010     Document Type: Review

References (173)

1. Yacoub MH, Miller LW. Long-term left-ventricular-assist-device therapy is here to stay. Nat Clin Pract Cardiovasc Med 2008; 5:60-61. An excellent review on the current state and future of LVAD therapy for heart failure.
2. Birks EJ, Tansley PD, Yacoub MH, et al. Incidence and clinical management of life-threatening left ventricular assist device failure. J Heart Lung Transplant 2004; 23:964-969.
3. Jessup M, Brozena S. Heart failure. N Engl J Med 2003; 348:2007-2018.
4. Sutton MG, Sharpe N. Left ventricular remodeling after myocardial infarction: pathophysiology and therapy. Circulation 2000; 101:2981-2988.
5. Bristow MR. Mechanisms of development of heart failure in the hypertensive patient. Cardiology 1999; 92 (Suppl 1):3-6.
6. Yancy CW, Fowler MB, Colucci WS, et al. Race and the response to adrenergic blockade with carvedilol in patients with chronic heart failure. N Engl J Med 2001; 344:1358-1365.
7. Birks EJ, Tansley PD, Hardy J, et al. Left ventricular assist device and drug therapy for the reversal of heart failure. N Engl J Med 2006; 355:1873-1884.
8. Frazier OH, Benedict CR, Radovancevic B, et al. Improved left ventricular function after chronic left ventricular unloading. Ann Thorac Surg 1996; 62:675-681.
9. Mancini DM, Beniaminovitz A, Levin H, et al. Low incidence of myocardial recovery after left ventricular assist device implantation in patients with chronic heart failure. Circulation 1998; 98:2383-2389.
10. Maybaum S, Mancini D, Xydas S, et al. Cardiac improvement during mechanical circulatory support: a prospective multicenter study of the LVAD Working Group. Circulation 2007; 115:2497-2505. First multicenter study reporting deleterious effects of chronic LVAD treatment of failing hearts.
11. Dandel M, Weng Y, Siniawski H, et al. Long-term results in patients with idiopathic dilated cardiomyopathy after weaning from left ventricular assist devices. Circulation 2005; 112:I37-I45.
12. Hetzer R, Muller JH, Weng Y, et al. Bridging-to-recovery. Ann Thorac Surg 2001; 71:S109-S113.
13. Yacoub MH. A novel strategy to maximize the efficacy of left ventricular assist devices as a bridge to recovery. Eur Heart J 2001; 22:534-540.
14. Ono K, Lindsey ES. Improved technique of heart transplantation in rats. J Thorac Cardiovasc Surg 1969; 57:225-229.
15. Oriyanhan W, Tsuneyoshi H, Nishina T, et al. Determination of optimal duration of mechanical unloading for failing hearts to achieve bridge to recovery in a rat heterotopic heart transplantation model. J Heart Lung Transplant 2007; 26:16-23. First experimental study showing deleterious effects of chronic mechanical unloading in failing rat hearts.
16. Tsuneyoshi H, Oriyanhan W, Kanemitsu H, et al. Heterotopic transplantation of the failing rat heart as a model of left ventricular mechanical unloading toward recovery. ASAIO J 2005; 51:116-120.
17. Soppa GKR, Lee J, Stagg MA, et al. Role and possible mechanisms of clenbuterol in enhancing reverse remodelling during mechanical unloading in murine heart failure. Cardiovasc Res 2008; 77:695-706. doi: 10.1093/cvr/cvm106.
18. 2+ regulation in rats with doxorubicin-induced cardiomyopathy. J Am Coll Cardiol 2004; 44:2239-2246.
19. Wang J, Marui A, Ikeda T, et al. Partial left ventricular unloading reverses contractile dysfunction and helps recover gene expressions in failing rat hearts. Interact Cardiovasc Thorac Surg 2008; 7:27-31.
20. Gupta MP. Factors controlling cardiac myosin-isoform shift during hypertrophy and heart failure. J Mol Cell Cardiol 2007; 43:388-403.
21. Palmer BM. Thick filament proteins and performance in human heart failure. Heart Fail Rev 2005; 10:187-197.
22. Ito K, Nakayama M, Hasan F, et al. Contractile reserve and calcium regulation are depressed in myocytes from chronically unloaded hearts. Circulation 2003; 107:1176-1182.
23. Klotz S, Foronjy RF, Dickstein ML, et al. Mechanical unloading during left ventricular assist device support increases left ventricular collagen cross-linking and myocardial stiffness. Circulation 2005; 112:364-374.
24. Bruggink AH, van Oosterhout MF, de Jong JN, et al. Reverse remodeling of the myocardial extracellular matrix after prolonged left ventricular assist device support follows a biphasic pattern. J Heart Lung Transplant 2006; 25:1091-1098.
25. Li YY, Feng Y, McTiernan CF, et al. Downregulation of matrix metalloproteinases and reduction in collagen damage in the failing human heart after support with left ventricular assist devices. Circulation 2001; 104:1147-1152.
26. Madigan JD, Barbone A, Choudhri AF, et al. Time course of reverse remodeling of the left ventricle during support with a left ventricular assist device. J Thorac Cardiovasc Surg 2001; 121:902-908.
27. Matsumiya G, Monta O, Fukushima N, et al. Who would be a candidate for bridge to recovery during prolonged mechanical left ventricular support in idiopathic dilated cardiomyopathy? J Thorac Cardiovasc Surg 2005; 130:699-704.
28. Soloff LA. Atrophy of myocardium and its myocytes by left ventricular assist device. Circulation 1999; 100:1012.
29. Rakusan K, Heron MI, Kolar F, et al. Transplantation-induced atrophy of normal and hypertrophic rat hearts: effect on cardiac myocytes and capillaries. J Mol Cell Cardiol 1997; 29:1045-1054.
30. Narula J, Haider N, Arbustini E, et al. Mechanisms of disease: apoptosis in heart failure - seeing hope in death. Nat Clin Pract Cardiovasc Med 2006; 3:681-688.
31. Narula J, Pandey P, Arbustini E, et al. Apoptosis in heart failure: release of cytochrome c from mitochondria and activation of caspase-3 in human cardiomyopathy. Proc Natl Acad Sci U S A 1999; 96:8144-8149.
32. Narula J, Haider N, Virmani R, et al. Apoptosis in myocytes in end-stage heart failure. N Engl J Med 1996; 335:1182-1189.
33. Garg S, Narula J, Chandrashekhar Y. Apoptosis and heart failure: clinical relevance and therapeutic target. J Mol Cell Cardiol 2005; 38:73-79.
34. Chandrashekhar Y, Sen S, Anway R, et al. Long-term caspase inhibition ameliorates apoptosis, reduces myocardial troponin-I cleavage, protects left ventricular function, and attenuates remodeling in rats with myocardial infarction. J Am Coll Cardiol 2004; 43:295-301.
35. Hayakawa K, Takemura G, Kanoh M, et al. Inhibition of granulation tissue cell apoptosis during the subacute stage of myocardial infarction improves cardiac remodeling and dysfunction at the chronic stage. Circulation 2003; 108:104-109.
36. Wencker D, Chandra M, Nguyen K, et al. A mechanistic role for cardiac myocyte apoptosis in heart failure. J Clin Invest 2003; 111:1497-1504.
37. Cascino I, Papoff G, De MR, et al. Fas/Apo-1 (CD95) receptor lacking the intracytoplasmic signaling domain protects tumor cells from Fas-mediated apoptosis. J Immunol 1996; 156:13-17.
38. Schumann H, Morawietz H, Hakim K, et al. Alternative splicing of the primary Fas transcript generating soluble Fas antagonists is suppressed in the failing human ventricular myocardium. Biochem Biophys Res Commun 1997; 239:794-798.
39. Bartling B, Milting H, Schumann H, et al. Myocardial gene expression of regulators of myocyte apoptosis and myocyte calcium homeostasis during hemodynamic unloading by ventricular assist devices in patients with end-stage heart failure. Circulation 1999; 100:II216-II223.
40. Milting H, Bartling B, Schumann H, et al. Altered levels of mRNA of apoptosis-mediating genes after mid-term mechanical ventricular support in dilative cardiomyopathy - first results of the Halle Assist Induced Recovery Study (HAIR). Thorac Cardiovasc Surg 1999; 47:48-50.
41. Chen Y, Park S, Li Y, et al. Alterations of gene expression in failing myocardium following left ventricular assist device support. Physiol Genomics 2003; 14:251-260.
42. Arbustini E, Morbini P, Narula N, et al. Apoptosis in heart failure: abrogation of mitochondrial cytochrome c release after ventricular unloading by LV assist device. Modern Pathol 2001; 14:43A. [abstract].
43. Francis GS, Anwar F, Bank AJ, et al. Apoptosis, Bcl-2, and proliferating cell nuclear antigen in the failing human heart: observations made after implantation of left ventricular assist device. J Card Fail 1999; 5:308-315.
44. de Jong N, van Wichen DF, van Kuik J, et al. Cardiomyocyte death in patients with end-stage heart failure before and after support with a left ventricular assist device: low incidence of apoptosis despite ubiquitous mediators. J Heart Lung Transplant 2003; 22:1028-1036.
45. Pearson G, Robinson F, Beers GT, et al. Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocr Rev 2001; 22:153-183.
46. Baba HA, Stypmann J, Grabellus F, et al. Dynamic regulation of MEK/Erks and Akt/GSK-3beta in human end-stage heart failure after left ventricular mechanical support: myocardial mechanotransduction-sensitivity as a possible molecular mechanism. Cardiovasc Res 2003; 59:390-399.
47. Ruwhof C, van der Laarse A. Mechanical stress-induced cardiac hypertrophy: mechanisms and signal transduction pathways. Cardiovasc Res 2000; 47:23-37.
48. Sugden PH. Mechanotransduction in cardiomyocyte hypertrophy. Circulation 2001; 103:1375-1377.
49. Baichwal VR, Baeuerle PA. Activate NF-kappa B or die? Curr Biol 1997; 7:R94-R96.
50. Wong SC, Fukuchi M, Melnyk P, et al. Induction of cyclooxygenase-2 and activation of nuclear factor-kappaB in myocardium of patients with congestive heart failure. Circulation 1998; 98:100-103.
51. Wohlschlaeger J, Schmitz KJ, Schmid C, et al. Reverse remodeling following insertion of left ventricular assist devices (LVAD): a review of the morphological and molecular changes. Cardiovasc Res 2005; 68:376-386.
52. Frantz S, Ertl G, Bauersachs J. Mechanisms of disease: Toll-like receptors in cardiovascular disease. Nat Clin Pract Cardiovasc Med 2007; 4:444-454. Excellent review on Toll-like receptors in cardiovascular disease.
53. Birks EJ, Felkin LE, Banner NR, et al. Increased toll-like receptor 4 in the myocardium of patients requiring left ventricular assist devices. J Heart Lung Transplant 2004; 23:228-235.
54. Birks EJ, Latif N, Owen V, et al. Quantitative myocardial cytokine expression and activation of the apoptotic pathway in patients who require left ventricular assist devices. Circulation 2001; 104:I233-I240.
55. Niebauer J, Volk HD, Kemp M, et al. Endotoxin and immune activation in chronic heart failure: a prospective cohort study. Lancet 1999; 353:1838-1842.
56. Mann DL, Young JB. Basic mechanisms in congestive heart failure. Recognizing the role of proinflammatory cytokines. Chest 1994; 105:897-904.
57. Habib FM, Springall DR, Davies GJ, et al. Tumour necrosis factor and inducible nitric oxide synthase in dilated cardiomyopathy. Lancet 1996; 347:1151-1155.
58. Torre-Amione G, Kapadia S, Benedict C, et al. Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol 1996; 27:1201-1206.
59. Levine B, Kalman J, Mayer L, et al. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 1990; 323:236-241.
60. Torre-Amione G, Stetson SJ, Youker KA, et al. Decreased expression of tumor necrosis factor-alpha in failing human myocardium after mechanical circulatory support: a potential mechanism for cardiac recovery. Circulation 1999; 100:1189-1193.
61. Razeghi P, Mukhopadhyay M, Myers TJ, et al. Myocardial tumor necrosis factor-alpha expression does not correlate with clinical indices of heart failure in patients on left ventricular assist device support. Ann Thorac Surg 2001; 72:2044-2050.
62. Kinoshita M, Takano H, Taenaka Y, et al. Cardiac disuse atrophy during LVAD pumping. ASAIO Trans 1988; 34:208-212.
63. Duerr RL, Huang S, Miraliakbar HR, et al. Insulin-like growth factor-1 enhances ventricular hypertrophy and function during the onset of experimental cardiac failure. J Clin Invest 1995; 95:619-627.
64. Welch S, Plank D, Witt S, et al. Cardiac-specific IGF-1 expression attenuates dilated cardiomyopathy in tropomodulin-overexpressing transgenic mice. Circ Res 2002; 90:641-648.
65. Musaro A, McCullagh KJ, Naya FJ, et al. IGF-1 induces skeletal myocyte hypertrophy through calcineurin in association with GATA-2 and NF-ATc1. Nature 1999; 400:581-585.
66. Musaro A, McCullagh K, Paul A, et al. Localized Igf-1 transgene expression sustains hypertrophy and regeneration in senescent skeletal muscle. Nat Genet 2001; 27:195-200.
67. Barton PJ, Felkin LE, Birks EJ, et al. Myocardial insulin-like growth factor-I gene expression during recovery from heart failure after combined left ventricular assist device and clenbuterol therapy. Circulation 2005; 112:I46-I50.
68. Sharma S, Ying J, Razeghi P, et al. Atrophic remodeling of the transplanted rat heart. Cardiology 2006; 105:128-136.
69. Razeghi P, Bruckner BA, Sharma S, et al. Mechanical unloading of the failing human heart fails to activate the protein kinase B/Akt/glycogen synthase kinase-3beta survival pathway. Cardiology 2003; 100:17-22.
70. Hall JL, Grindle S, Han X, et al. Genomic profiling of the human heart before and after mechanical support with a ventricular assist device reveals alterations in vascular signaling networks. Physiol Genomics 2004; 17:283-291.
71. Torella D, Rota M, Nurzynska D, et al. Cardiac stem cell and myocyte aging, heart failure, and insulin-like growth factor-1 overexpression. Circ Res 2004; 94:514-524.
72. Santini MP, Tsao L, Monassier L, s Enhancing repair of the mammalian heart. Circ Res 2007; 100:1732-1740. Important study elucidating role and mechanisms of IGF-1 induced myocardial regeneration after injury.
73. Harrison CA, Gray PC, Vale WW, et al. Antagonists of activin signaling: mechanisms and potential biological applications. Trends Endocrinol Metab 2005; 16:73-78.
74. Lara-Pezzi E, Felkin LE, Sarathchandra P, et al. A potentially novel role of the follistatin-activin pathway in heart failure and myocardial recovery following LVAD combination therapy. Circulation 2007; 116:II_541. [abstract].
75. Tansley P, Yacoub M, Rimoldi O, et al. Effect of left ventricular assist device combination therapy on myocardial blood flow in patients with end-stage dilated cardiomyopathy. J Heart Lung Transplant 2004; 23:1283-1289.
76. Oka T, Xu J, Molkentin JD. Re-employment of developmental transcription factors in adult heart disease. Semin Cell Dev Biol 2007; 18:117-131.
77. Olson EN, Schneider MD. Sizing up the heart: development redux in disease. Genes Dev 2003; 17:1937-1956.
78. Izumo S, Nadal-Ginard B, Mahdavi V. Protooncogene induction and reprogramming of cardiac gene expression produced by pressure overload. Proc Natl Acad Sci U S A 1988; 85:339-343.
79. Srivastava D, Thomas T, Lin Q, et al. Regulation of cardiac mesodermal and neural crest development by the bHLH transcription factor, dHAND. Nat Genet 1997; 16:154-160.
80. Bhattacharya S, Macdonald ST, Farthing CR. Molecular mechanisms controlling the coupled development of myocardium and coronary vasculature. Clin Sci (Lond) 2006; 111:35-46.
81. Natarajan A, Yamagishi H, Ahmad F, et al. Human eHAND, but not dHAND, is down-regulated in cardiomyopathies. J Mol Cell Cardiol 2001; 33:1607-1614.
82. Barton PJ, Felkin LE, Lara-Pezzi E, et al. HAND1 gene expression is down regulated during myocardial recovery from heart failure and is associated with mitochondrial energy pathways. Circulation 2007; 116:II_732. [abstract].
83. Gwathmey JK, Copelas L, MacKinnon R, et al. Abnormal intracellular calcium handling in myocardium from patients with end-stage heart failure. Circ Res 1987; 61:70-76.
84. Morgan JP, Erny RE, Allen PD, et al. Abnormal intracellular calcium handling, a major cause of systolic and diastolic dysfunction in ventricular myocardium from patients with heart failure. Circulation 1990; 81:III21-III32.
85. Heerdt PM, Holmes JW, Cai B, et al. Chronic unloading by left ventricular assist device reverses contractile dysfunction and alters gene expression in end-stage heart failure. Circulation 2000; 102:2713-2719.
86. Rodrigue-Way A, Burkhoff D, Geesaman BJ, et al. Sarcomeric genes involved in reverse remodeling of the heart during left ventricular assist device support. J Heart Lung Transplant 2005; 24:73-80.
87. Heerdt PM, Klotz S, Burkhoff D. Cardiomyopathic etiology and SERCA2a reverse remodeling during mechanical support of the failing human heart. Anesth Analg 2006; 102:32-37.
88. Terracciano CM, Hardy J, Birks EJ, et al. Clinical recovery from end-stage heart failure using left-ventricular assist device and pharmacological therapy correlates with increased sarcoplasmic reticulum calcium content but not with regression of cellular hypertrophy. Circulation 2004; 109:2263-2265.
89. Terracciano CM, Harding SE, Adamson D, et al. Changes in sarcolemmal Ca entry and sarcoplasmic reticulum Ca content in ventricular myocytes from patients with end-stage heart failure following myocardial recovery after combined pharmacological and ventricular assist device therapy. Eur Heart J 2003; 24:1329-1339.
90. Dipla K, Mattiello JA, Jeevanandam V, et al. Myocyte recovery after mechanical circulatory support in humans with end-stage heart failure. Circulation 1998; 97:2316-2322.
91. Marx SO, Reiken S, Hisamatsu Y, et al. PKA phosphorylation dissociates FKBP12.6 from the calcium release channel (ryanodine receptor): defective regulation in failing hearts. Cell 2000; 101:365-376.
92. Harding JD, Piacentino V III, Gaughan JP, et al. Electrophysiological alterations after mechanical circulatory support in patients with advanced cardiac failure. Circulation 2001; 104:1241-1247.
93. 2+ channel density and regulation are altered in failing human ventricular myocytes and recover after support with mechanical assist devices. Circ Res 2002; 91:517-524.
94. 2+ cycling after left ventricular assist device support in the failing human heart. J Am Coll Cardiol 2004; 44:837-845.
95. 2+ exchanger in reverse remodeling: relevance for LVAD recovery. Ann N Y Acad Sci 2007; 1099:349-360.
96. Xiao RP, Zhu W, Zheng M, et al. Subtype-specific beta-adrenoceptor signaling pathways in the heart and their potential clinical implications. Trends Pharmacol Sci 2004; 25:358-365.
97. Bristow MR, Ginsburg R, Minobe W, et al. Decreased catecholamine sensitivity and beta-adrenergic-receptor density in failing human hearts. N Engl J Med 1982; 307:205-211.
98. Davies CH, Davia K, Bennett JG, et al. Reduced contraction and altered frequency response of isolated ventricular myocytes from patients with heart failure. Circulation 1995; 92:2540-2549.
99. Feldman MD, Copelas L, Gwathmey JK, et al. Deficient production of cyclic AMP: pharmacologic evidence of an important cause of contractile dysfunction in patients with end-stage heart failure. Circulation 1987; 75:331-339.
100. Engelhardt S, Bohm M, Erdmann E, et al. Analysis of beta-adrenergic receptor mRNA levels in human ventricular biopsy specimens by quantitative polymerase chain reactions: progressive reduction of beta 1-adrenergic receptor mRNA in heart failure. J Am Coll Cardiol 1996; 27:146-154.
101. Ungerer M, Parruti G, Bohm M, et al. Expression of beta-arrestins and betaadrenergic receptor kinases in the failing human heart. Circ Res 1994; 74:206-213.
102. Ungerer M, Bohm M, Elce JS, et al. Altered expression of beta-adrenergic receptor kinase and beta 1-adrenergic receptors in the failing human heart. Circulation 1993; 87:454-463.
103. Owen VJ, Burton PB, Mullen AJ, et al. Expression of RGS3, RGS4 and Gi alpha 2 in acutely failing donor hearts and end-stage heart failure. Eur Heart J 2001; 22:1015-1020.
104. Akhter SA, Eckhart AD, Rockman HA, et al. In vivo inhibition of elevated myocardial beta-adrenergic receptor kinase activity in hybrid transgenic mice restores normal beta-adrenergic signaling and function. Circulation 1999; 100:648-653.
105. Brodde OE. Beta-adrenoceptors in cardiac disease. Pharmacol Ther 1993; 60:405-430.
106. Chesley A, Lundberg MS, Asai T, et al. The beta(2)-adrenergic receptor delivers an antiapoptotic signal to cardiac myocytes through G(i)-dependent coupling to phosphatidylinositol 3′-kinase. Circ Res 2000; 87:1172-1179.
107. Ahmet I, Lakatta EG, Talan MI. Pharmacological stimulation of beta (2)-adrenergic receptors (beta (2)AR) enhances therapeutic effectiveness of beta (1)AR blockade in rodent dilated ischemic cardiomyopathy. Heart Fail Rev 2005; 10:289-296.
108. Ahmet I, Krawczyk M, Heller P, et al. Beneficial effects of chronic pharmacological manipulation of beta-adrenoreceptor subtype signaling in rodent dilated ischemic cardiomyopathy. Circulation 2004; 110:1083-1090.
109. Ponicke K, Heinroth-Hoffmann I, Brodde OE. Role of beta 1- and beta 2-adrenoceptors in hypertrophic and apoptotic effects of noradrenaline and adrenaline in adult rat ventricular cardiomyocytes. Naunyn Schmiedebergs Arch Pharmacol 2003; 367:592-599.
110. Communal C, Singh K, Sawyer DB, et al. Opposing effects of beta(1)- and beta(2)-adrenergic receptors on cardiac myocyte apoptosis: role of a pertussis toxin-sensitive G protein. Circulation 1999; 100:2210-2212.
111. Zhu WZ, Zheng M, Koch WJ, et al. Dual modulation of cell survival and cell death by beta(2)-adrenergic signaling in adult mouse cardiac myocytes. Proc Natl Acad Sci U S A 2001; 98:1607-1612.
112. Xiao RP. Beta-adrenergic signaling in the heart: dual coupling of the beta2-adrenergic receptor to G(s) and G(i) proteins. Sci STKE 2001; 2001: RE15.
113. Tevaearai HT, Eckhart AD, Walton GB, et al. Myocardial gene transfer and overexpression of beta2-adrenergic receptors potentiates the functional recovery of unloaded failing hearts. Circulation 2002; 106:124-129.
114. Xydas S, Kherani AR, Chang JS, et al. {beta}-2 Adrenergic stimulation attenuates left ventricular remodeling, decreases apoptosis, and improves calcium homeostasis in a rodent model of ischemic cardiomyopathy. J Pharmacol Exp Ther 2006; 317:553-561.
115. Ogletree-Hughes ML, Stull LB, Sweet WE, et al. Mechanical unloading restores beta-adrenergic responsiveness and reverses receptor downregulation in the failing human heart. Circulation 2001; 104:881-886.
116. Klotz S, Barbone A, Reiken S, et al. Left ventricular assist device support normalizes left and right ventricular beta-adrenergic pathway properties. J Am Coll Cardiol 2005; 45:668-676.
117. Woodcock EA. Roles of alpha1A- and alpha1B-adrenoceptors in heart: insights from studies of genetically modified mice. Clin Exp Pharmacol Physiol 2007; 34:884-888.
118. Smiley RM, Kwatra MM, Schwinn DA. New developments in cardiovascular adrenergic receptor pharmacology: molecular mechanisms and clinical relevance. J Cardiothorac Vasc Anesth 1998; 12:80-95.
119. Schwinn DA. Adrenoceptors as models for G protein-coupled receptors: structure, function and regulation. Br J Anaesth 1993; 71:77-85.
120. Bohm M, Diet F, Feiler G, et al. Alpha-adrenoceptors and alpha-adrenoceptor-mediated positive inotropic effects in failing human myocardium. J Cardiovasc Pharmacol 1988; 12:357-364.
121. Grigore A, Poindexter B, Vaughn WK, et al. Alterations in alpha adrenoreceptor density and localization after mechanical left ventricular unloading with the Jarvik flowmaker left ventricular assist device. J Heart Lung Transplant 2005; 24:609-613.
122. Vatta M, Stetson SJ, Perez-Verdia A, et al. Molecular remodelling of dystrophin in patients with end-stage cardiomyopathies and reversal in patients on assistance-device therapy. Lancet 2002; 359:936-941.
123. Vatta M, Stetson SJ, Jimenez S, et al. Molecular normalization of dystrophin in the failing left and right ventricle of patients treated with either pulsatile or continuous flow-type ventricular assist devices. J Am Coll Cardiol 2004; 43:811-817.
124. Birks EJ, Hall JL, Barton PJ, et al. Gene profiling changes in cytoskeletal proteins during clinical recovery after left ventricular-assist device support. Circulation 2005; 112:I57-I64.
125. Latif N, Yacoub MH, George R, et al. Changes in sarcomeric and nonsarcomeric cytoskeletal proteins and focal adhesion molecules during clinical myocardial recovery after left ventricular assist device support. J Heart Lung Transplant 2007; 26:230-235.
126. Hall JL, Birks EJ, Grindle S, et al. Molecular signature of recovery following combination left ventricular assist device (LVAD) support and pharmacologic therapy. Eur Heart J 2007; 28:613-627.
127. de Jonge N, van Wichen DF, Schipper ME, et al. Left ventricular assist device in end-stage heart failure: persistence of structural myocyte damage after unloading. An immunohistochemical analysis of the contractile myofilaments. J Am Coll Cardiol 2002; 39:963-969.
128. Ashrafian H, Frenneaux MP, Opie LH. Metabolic mechanisms in heart failure. Circulation 2007; 116:434-448. Excellent review of changes in metabolic pathways and mechanisms in heart failure.
129. Lee SH, Doliba N, Osbakken M, et al. Improvement of myocardial mitochondrial function after hemodynamic support with left ventricular assist devices in patients with heart failure. J Thorac Cardiovasc Surg 1998; 116:344-349.
130. Jiang F, Ryan MT, Schlame M, et al. Absence of cardiolipin in the crd1 null mutant results in decreased mitochondrial membrane potential and reduced mitochondrial function. J Biol Chem 2000; 275:22387-22394.
131. Ohtsuka T, Nishijima M, Suzuki K, et al. Mitochondrial dysfunction of a cultured Chinese hamster ovary cell mutant deficient in cardiolipin. J Biol Chem 1993; 268:22914-22919.
132. Paradies G, Petrosillo G, Gadaleta MN, et al. The effect of aging and acetyl-L-carnitine on the pyruvate transport and oxidation in rat heart mitochondria. FEBS Lett 1999; 454:207-209.
133. Heerdt PM, Schlame M, Jehle R, et al. Disease-specific remodeling of cardiac mitochondria after a left ventricular assist device. Ann Thorac Surg 2002; 73:1216-1221.
134. Mital S, Loke KE, Addonizio LJ, et al. Left ventricular assist device implantation augments nitric oxide dependent control of mitochondrial respiration in failing human hearts. J Am Coll Cardiol 2000; 36:1897-1902.
135. Razeghi P, Young ME, Ying J, et al. Downregulation of metabolic gene expression in failing human heart before and after mechanical unloading. Cardiology 2002; 97:203-209.
136. Ingwall JS, Weiss RG. Is the failing heart energy starved? On using chemical energy to support cardiac function. Circ Res 2004; 95:135-145.
137. Nascimben L, Ingwall JS, Pauletto P, et al. Creatine kinase system in failing and nonfailing human myocardium. Circulation 1996; 94:1894-1901.
138. Starling RC, Hammer DF, Altschuld RA. Human myocardial ATP content and in vivo contractile function. Mol Cell Biochem 1998; 180:171-177.
139. Beer M, Seyfarth T, Sandstede J, et al. Absolute concentrations of high-energy phosphate metabolites in normal, hypertrophied, and failing human myocardium measured noninvasively with (31)P-SLOOP magnetic resonance spectroscopy. J Am Coll Cardiol 2002; 40:1267-1274.
140. Nakae I, Mitsunami K, Omura T, et al. Proton magnetic resonance spectroscopy can detect creatine depletion associated with the progression of heart failure in cardiomyopathy. J Am Coll Cardiol 2003; 42:1587-1593.
141. Cullen ME, Yuen AH, Felkin LE, et al. Myocardial expression of the arginine : glycine amidinotransferase gene is elevated in heart failure and normalized after recovery: potential implications for local creatine synthesis. Circulation 2006; 114:I16-I20.
142. Di Lullo GA, Sweeney SM, Korkko J, et al. Mapping the ligand-binding sites and disease-associated mutations on the most abundant protein in the human, type I collagen. J Biol Chem 2002; 277:4223-4231.
143. Akgul A, Skrabal CA, Thompson LO, et al. Role of mast cells and their mediators in failing myocardium under mechanical ventricular support. J Heart Lung Transplant 2004; 23:709-715.
144. Bruckner BA, Stetson SJ, Perez-Verdia A, et al. Regression of fibrosis and hypertrophy in failing myocardium following mechanical circulatory support. J Heart Lung Transplant 2001; 20:457-464.
145. Bruckner BA, Stetson SJ, Farmer JA, et al. The implications for cardiac recovery of left ventricular assist device support on myocardial collagen content. Am J Surg 2000; 180:498-501.
146. Thompson LO, Skrabal CA, Loebe M, et al. Plasma neurohormone levels correlate with left ventricular functional and morphological improvement in LVAD patients. J Surg Res 2005; 123:25-32.
147. Milting H, Kassner A, Arusoglu L, et al. Influence of ACE-inhibition and mechanical unloading on the regulation of extracellular matrix proteins in the myocardium of heart transplantation candidates bridged by ventricular assist devices. Eur J Heart Fail 2006; 8:278-283.
148. Klotz S, Danser AH, Foronjy RF, et al. The impact of angiotensin-converting enzyme inhibitor therapy on the extracellular collagen matrix during left ventricular assist device support in patients with end-stage heart failure. J Am Coll Cardiol 2007; 49:1166-1174. Important study showing pharmacological manipulation of ECM during LVAD treatment.
149. Norton GR, Tsotetsi J, Trifunovic B, et al. Myocardial stiffness is attributed to alterations in cross-linked collagen rather than total collagen or phenotypes in spontaneously hypertensive rats. Circulation 1997; 96:1991-1998.
150. Li YY, Feldman AM, Sun Y, et al. Differential expression of tissue inhibitors of metalloproteinases in the failing human heart. Circulation 1998; 98:1728-1734.
151. Spinale FG, Coker ML, Heung LJ, et al. A matrix metalloproteinase induction/activation system exists in the human left ventricular myocardium and is upregulated in heart failure. Circulation 2000; 102:1944-1949.
152. Wilson EM, Spinale FG. Myocardial remodelling and matrix metalloproteinases in heart failure: turmoil within the interstitium. Ann Med 2001; 33:623-634.
153. Felkin LE, Birks EJ, George R, et al. A quantitative gene expression profile of matrix metalloproteinases (MMPS) and their inhibitors (TIMPS) in the myocardium of patients with deteriorating heart failure requiring left ventricular assist device support. J Heart Lung Transplant 2006; 25:1413-1419.
154. Bruckner BA, Razeghi P, Stetson S, et al. Degree of cardiac fibrosis and hypertrophy at time of implantation predictsmyocardial improvement during left ventricular assist device support. J Heart Lung Transplant 2004; 23:36-42.
155. Towbin JA. Scarring in the heart - a reversible phenomenon? N Engl J Med 2007; 357:1767-1768.
156. Felkin LE, Lara-Pezzi E, George R, et al. Myocardial expression of extracellular matrix genes during LVAD combination therapy - relevance to recovery. Circulation 2007; 116:II_733. [abstract]. First study showing specific changes in ECM may be associated with improved myocardial recovery after LVAD treatment.
157. Camici PG, Crea F. Coronary microvascular dysfunction. N Engl J Med 2007; 356:830-840.
158. Weiss MB, Ellis K, Sciacca RR, et al. Myocardial blood flow in congestive and hypertrophic cardiomyopathy: relationship to peak wall stress and mean velocity of circumferential fiber shortening. Circulation 1976; 54:484-494.
159. Neglia D, Parodi O, Gallopin M, et al. Myocardial blood flow response to pacing tachycardia and to dipyridamole infusion in patients with dilated cardiomyopathy without overt heart failure. A quantitative assessment by positron emission tomography. Circulation 1995; 92:796-804.
160. Huebert RC, Li Q, Adhikari N, et al. Identification and regulation of Sprouty1, a negative inhibitor of the ERK cascade, in the human heart. Physiol Genomics 2004; 18:284-289.
161. Affara M, Dunmore B, Savoie C, et al. Understanding endothelial cell apoptosis: what can the transcriptome, glycome and proteome reveal? Philos Trans R Soc Lond B Biol Sci 2007; 362:1469-1487.
162. Penna C, Rastaldo R, Mancardi D, et al. Effect of endothelins on the cardiovascular system. J Cardiovasc Med (Hagerstown) 2006; 7:645-652.
163. Morawietz H, Szibor M, Goettsch W, et al. Deloading of the left ventricle by ventricular assist device normalizes increased expression of endothelin ET(A) receptors but not endothelin-converting enzyme-1 in patients with end-stage heart failure. Circulation 2000; 102:III188-III193.
164. Milting H, EL BA, Kassner A, et al. The time course of natriuretic hormones as plasma markers of myocardial recovery in heart transplant candidates during ventricular assist device support reveals differences among device types. J Heart Lung Transplant 2001; 20:949-955.
165. James KB, McCarthy PM, Thomas JD, et al. Effect of the implantable left ventricular assist device on neuroendocrine activation in heart failure. Circulation 1995; 92:II191-II195.
166. Szokodi I, Tavi P, Foldes G, et al. Apelin, the novel endogenous ligand of the orphan receptor APJ, regulates cardiac contractility. Circ Res 2002; 91:434-440.
167. Berry MF, Pirolli TJ, Jayasankar V, et al. Apelin has in vivo inotropic effects on normal and failing hearts. Circulation 2004; 110:II187-II193.
168. Chong KS, Gardner RS, Morton JJ, et al. Plasma concentrations of the novel peptide apelin are decreased in patients with chronic heart failure. Eur J Heart Fail 2006; 8:355-360.
169. Atluri P, Morine KJ, Liao GP, et al. Ischemic heart failure enhances endogenous myocardial apelin and APJ receptor expression. Cell Mol Biol Lett 2007; 12:127-138.
170. Chen MM, Ashley EA, Deng DX, et al. Novel role for the potent endogenous inotrope apelin in human cardiac dysfunction. Circulation 2003; 108:1432-1439.
171. Farkasfalvi K, Felkin L, Latif N, et al. The apelin receptor mRNA levels and myocardial recovery in end-stage heart failure patients treated with left ventricular assist devices (LVADs) [abstract]. Circulation 2006; 114:484.
172. Blaxall BC, Tschannen-Moran BM, Milano CA, et al. Differential gene expression and genomic patient stratification following left ventricular assist device support. J Am Coll Cardiol 2003; 41:1096-1106.
173. Margulies KB, Matiwala S, Cornejo C, et al. Mixed messages: transcription patterns in failing and recovering human myocardium. Circ Res 2005; 96:592-599.